A Comparison of Single Dose Rasburicase 3 Mg Versus 6 Mg for the Management of Tumor Lysis Syndrome

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults.

Rasburicase is currently approved at a dosage of 0.15-0.2 mg/kg once/day for 5 days in pediatric patients with cancer to lower plasma uric acid concentrations and manage tumor lysis syndrome (TLS). Information on rasburicase dosing in adults is limited, with some data on using rasburicase as a single dose instead of multiple daily doses. Therefore, we evaluated the efficacy of a single dose of ...

متن کامل

The Efficacy of Single Dose Rasburicase in Prevention or Treatment of Tumor Lysis Syndrome in Children

Background: Tumor lysis syndrome (TLS) is a major metabolic complication in patients with malignancy after initiation of chemotherapy or spontaneously without treatment. The role of Rasburicase (a recombinant urate-oxidase enzyme) in prevention and treatment of TLS has been demonstrated in recent years. We aimed to investigate the efficacy of a single dose of rasburicase in reducing the risk of...

متن کامل

the efficacy of single dose rasburicase in prevention or treatment of tumor lysis syndrome in children

background: tumor lysis syndrome (tls) is a major metabolic complication in patients with malignancy after initiation of chemotherapy or spontaneously without treatment. the role of rasburicase (a recombinant urate-oxidase enzyme) in prevention and treatment of tls has been demonstrated in recent years. we aimed to investigate the efficacy of a single dose of rasburicase in reducing the risk of...

متن کامل

Rasburicase (Elitek): a novel agent for tumor lysis syndrome.

The overall incidence of tumor lysis syndrome in adults is not well defined, and its occurrence can be unpredictable. Several strategies are available for the prevention and treatment of tumor lysis syndrome, with rasburicase being the most recent. Rasburicase is a recombinant urate oxidase enzyme approved for use by the Food and Drug Administration in patients who are at risk of developing tum...

متن کامل

Rasburicase for prevention of hyperuricemia and tumor lysis syndrome.

• Hyperuricemia associated with tumor lysis syndrome is a potentially serious complication most frequently seen during chemotherapy for malignancies with large tumor burden and highly proliferative cells, such as aggressive lymphomas and leukemia.1-3 Hyperuricemia usually occurs in association with other metabolic abnormalities, including hyperphosphatemia, hyperkalemia, hypocalcemia, and azote...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Blood

سال: 2015

ISSN: 0006-4971,1528-0020

DOI: 10.1182/blood.v126.23.4511.4511